ScholarIQanswers from OpenAlex & ORCID
Jack A. Roth
ResearcherPublications, citations & collaboration network
Jack A. Roth is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Jack A. Roth have?
ScholarIQindexed works
Jack A. Roth has 1,235 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Jack A. Roth have?
ScholarIQcitation count
Jack A. Roth has 59,169 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Jack A. Roth?
ScholarIQh-index
Jack A. Roth has an h-index of 117 in OpenAlex.
What is the i10-index of Jack A. Roth?
ScholarIQi10-index
Jack A. Roth has an i10-index of 564 in OpenAlex.
What is the ORCID of Jack A. Roth?
ScholarIQorcid
The ORCID for Jack A. Roth is on the source record.
What is the OpenAlex record for Jack A. Roth?
ScholarIQopenalex
The OpenAlex for Jack A. Roth is on the source record.
What are the most-cited papers on Jack A. Roth?
ScholarIQmost cited works
Chemotherapy Followed by Surgery Compared with Surgery Alone for Localized Esophageal Cancer
David P. Kelsen, Robert J. Ginsberg, Thomas F. Pajak, Daniel G. Sheahan, Leonard L. Gunderson, Joanne Mortimer, Norman Estes, Daniel G. Haller, Jaffer A. Ajani, Walter Kocha, Bruce D. Minsky, Jack A. Roth
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
Carl M. Gay, C. Allison Stewart, Elizabeth M. Park, Lixia Diao, Sarah M. Groves, Simon Heeke, Barzin Y. Nabet, Junya Fujimoto, Luisa M. Solis, Wei Lü, Yuanxin Xi, Robert J. Cardnell, Qi Wang, Giulia Fabbri, Kasey R. Cargill, Natalie I. Vokes, Kavya Ramkumar, Bingnan Zhang, Carminia Maria Della Corte, Paul Robson, Stephen G. Swisher, Jack A. Roth, Bonnie S. Glisson, David S. Shames, Ignacio I. Wistuba, Jing Wang, Vito Quaranta, John D. Minna, John V. Heymach, Lauren A. Byers
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
Tina Cascone, William N. William, Annikka Weissferdt, Cheuk Hong Leung, Heather Lin, Apar Pataer, Myrna C. B. Godoy, Brett W. Carter, Lorenzo Federico, Alexandre Reuben, M.A. Wadud Khan, Hitoshi Dejima, Alejandro Francisco‐Cruz, Edwin R. Parra, Luisa M. Solis, Junya Fujimoto, Hai T. Tran, Neda Kalhor, Frank V. Fossella, Frank E. Mott, Anne S. Tsao, George Blumenschein, Xiuning Le, Jianjun Zhang, Ferdinandos Skoulidis, Jonathan M. Kurie, Mehmet Altan, Charles Lu, Bonnie S. Glisson, Lauren A. Byers, Yasir Y. Elamin, Reza J. Mehran, David C. Rice, Garrett L. Walsh, Wayne L. Hofstetter, Jack A. Roth, Mara B. Antonoff, Humam Kadara, Cara Haymaker, Chantale Bernatchez, Nadim J. Ajami, Robert R. Jenq, Padmanee Sharma, James P. Allison, P. Andrew Futreal, Jennifer A. Wargo, Ignacio I. Wistuba, Stephen G. Swisher, J. Jack Lee, Don L. Gibbons, Ara A. Vaporciyan, John V. Heymach, Boris Sepesi
Long-Term Results of RTOG Trial 8911 (USA Intergroup 113): A Random Assignment Trial Comparison of Chemotherapy Followed by Surgery Compared With Surgery Alone for Esophageal Cancer
David P. Kelsen, Katryn A. Winter, Leonard L. Gunderson, Joanne Mortimer, Norman Estes, Daniel G. Haller, Jaffer A. Ajani, Walter Kocha, Bruce D. Minsky, Jack A. Roth, Christopher G. Willett
Adenovirus-Mediated p53 Gene Transfer in Advanced Non-Small-Cell Lung Cancer
Stephen G. Swisher, Jack A. Roth, John Nemunaitis, D D Lawrence, B L Kemp, C. Humberto Carrasco, D. G. Connors, Adel K. El‐Naggar, Frank V. Fossella, Bonnie S. Glisson, Waun Ki Hong, Fadlo R. Khuri, Jonathan M. Kurie, J. J. Lee, J. S. Lee, Michael J. Mack, James A. Merritt, Dao Nguyen, Jonathan C. Nesbitt, Román Pérez-Soler, K. M. W. Pisters, Joe B. Putnam, William R. Richli, Michael A. Savin, David S. Schrump, Dong M. Shin, Allan N. Shulkin, G. Walsh, Juliette Wait, David Weill, Martin Waugh